ASH 2017 – ITP

Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP). Read More ›

The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP). Read More ›

The current post-hoc subanalysis of a phase 4 open-label study concluded that the effects on platelet counts after eltrombopag treatment for >2 years was comparable between the persistent immune thrombocytopenia (ITP) and the chronic ITP cohorts, with similar safety profiles. Read More ›

These study results showed that heavily pretreated patients with persistent/chronic immune thrombocytopenia (ITP) who achieved a stable response with fostamatinib therapy maintained their responses for ≥12 months. Read More ›

This open-label study reported that the majority of children with immune thrombocytopenia (ITP) who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 10⁹/L from week 12 onward and no new safety signals observed during the study period. Read More ›